Etanercept

Generic Name
Etanercept
Brand Names
Enbrel, Eticovo, Benepali, Erelzi, Nepexto
Drug Type
Biotech
Chemical Formula
-
CAS Number
185243-69-0
Unique Ingredient Identifier
OP401G7OJC
Background

Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technolo...

Indication

Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis and Juvenile Psoriatic Arthritis in those aged 2 years and older. Etanercept is al...

Associated Conditions
Active Juvenile Psoriatic Arthritis, Ankylosing Spondylitis (AS), Graft-versus-host Disease (GVHD), Polyarticular Juvenile Idiopathic Arthritis, Psoriasis Vulgaris (Plaque Psoriasis), Psoriatic Arthritis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Plaque psoriasis, Stevens-Johnson Syndrome, Chronic, severe Psoriatic Arthritis, Moderate Plaque psoriasis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis
Associated Therapies
-
Clinical Trials
Related News

An Evaluation of Etanercept in the Treatment of Subjects With Psoriasis

Phase 3
Completed
Conditions
Psoriasis
First Posted Date
2005-05-18
Last Posted Date
2009-05-29
Lead Sponsor
Amgen
Registration Number
NCT00111111

Utilization of Narrow Band Ultraviolet B (UVB) Light Therapy and Etanercept for the Treatment of Psoriasis

Phase 4
Completed
Conditions
Psoriasis
Interventions
Device: NB-UVB
Drug: Etanerept
Drug: Etanercept
First Posted Date
2005-05-17
Last Posted Date
2013-05-24
Lead Sponsor
Amgen
Target Recruit Count
86
Registration Number
NCT00110981

Etanercept for Treatment of Hidradenitis

Phase 2
Completed
Conditions
Hidradenitis Suppurativa
Interventions
Drug: etanercept
First Posted Date
2005-04-12
Last Posted Date
2018-03-21
Lead Sponsor
University of Pennsylvania
Target Recruit Count
15
Registration Number
NCT00107991

Effectiveness and Safety of Enbrel® (Etanercept) in Rheumatoid Arthritis Subjects Who Have Failed Remicade® (Infliximab)

Phase 4
Completed
Conditions
Rheumatoid Arthritis
First Posted Date
2004-12-17
Last Posted Date
2009-11-13
Lead Sponsor
Amgen
Target Recruit Count
200
Registration Number
NCT00099554

Preference of Rheumatoid Arthritis (RA) Patients of Enbrel® (Etanercept) Auto-Injector Versus Enbrel® Pre-Filled Syringes

Phase 4
Completed
Conditions
Rheumatoid Arthritis
First Posted Date
2004-10-18
Last Posted Date
2008-12-05
Lead Sponsor
Amgen
Target Recruit Count
215
Registration Number
NCT00094341

Etanercept (Enbrel®) in Psoriasis - Pediatrics

Phase 3
Completed
Conditions
Psoriasis
Interventions
Drug: Placebo
Drug: Etanercept
First Posted Date
2004-03-09
Last Posted Date
2019-07-29
Lead Sponsor
Amgen
Target Recruit Count
211
Registration Number
NCT00078819

Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis

Phase 3
Terminated
Conditions
Juvenile Rheumatoid Arthritis
Interventions
Drug: Etanercept
Drug: Placebo
First Posted Date
2004-03-09
Last Posted Date
2019-09-25
Lead Sponsor
Amgen
Target Recruit Count
19
Registration Number
NCT00078806

Study Evaluating the Safety and Efficacy of Etanercept in Patients With Idiopathic Pulmonary Fibrosis

Phase 2
Completed
Conditions
Pulmonary Fibrosis
First Posted Date
2003-07-09
Last Posted Date
2009-09-04
Lead Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Target Recruit Count
88
Registration Number
NCT00063869

Treatment of Resistant Langerhans Cell Histiocytosis With ENBREL

Phase 2
Completed
Conditions
Histiocytosis, Langerhans-Cell
First Posted Date
2002-11-01
Last Posted Date
2020-01-09
Lead Sponsor
Baylor College of Medicine
Target Recruit Count
20
Registration Number
NCT00048373
Locations
🇺🇸

Texas Children's Hospital, Houston, Texas, United States

Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis

Phase 2
Terminated
Conditions
Dermatomyositis
First Posted Date
2002-05-08
Last Posted Date
2013-08-01
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Target Recruit Count
75
Registration Number
NCT00035958
Locations
🇺🇸

Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy